Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
about
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies.Roflumilast restores cAMP/PKA/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer.A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
P2860
Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Safety and Pharmacodynamics of ...... Advanced B-cell Malignancies.
@en
Safety and Pharmacodynamics of ...... Advanced B-cell Malignancies.
@nl
type
label
Safety and Pharmacodynamics of ...... Advanced B-cell Malignancies.
@en
Safety and Pharmacodynamics of ...... Advanced B-cell Malignancies.
@nl
prefLabel
Safety and Pharmacodynamics of ...... Advanced B-cell Malignancies.
@en
Safety and Pharmacodynamics of ...... Advanced B-cell Malignancies.
@nl
P2093
P2860
P1476
Safety and Pharmacodynamics of ...... Advanced B-cell Malignancies.
@en
P2093
Alex Mejia
An-Ping Lin
Anand B Karnad
Avvaru N Suhasini
Kevin Kelly
Ricardo C T Aguiar
Steven Weitman
P2860
P304
P356
10.1158/1078-0432.CCR-16-1207
P407
P577
2016-08-19T00:00:00Z